Cargando…
ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study
Background and objectives: In light of the growing burden of chronic kidney disease (CKD), it is of particular importance to create disease prediction models that can assist healthcare providers in identifying cases of CKD individual risk and integrate risk-based care for disease progress management...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965616/ https://www.ncbi.nlm.nih.gov/pubmed/36836039 http://dx.doi.org/10.3390/jcm12041504 |
_version_ | 1784896809441689600 |
---|---|
author | Hui, Miao Ma, Jun Yang, Hongyu Gao, Bixia Wang, Fang Wang, Jinwei Lv, Jicheng Zhang, Luxia Yang, Li Zhao, Minghui |
author_facet | Hui, Miao Ma, Jun Yang, Hongyu Gao, Bixia Wang, Fang Wang, Jinwei Lv, Jicheng Zhang, Luxia Yang, Li Zhao, Minghui |
author_sort | Hui, Miao |
collection | PubMed |
description | Background and objectives: In light of the growing burden of chronic kidney disease (CKD), it is of particular importance to create disease prediction models that can assist healthcare providers in identifying cases of CKD individual risk and integrate risk-based care for disease progress management. The objective of this study was to develop and validate a new pragmatic end-stage kidney disease (ESKD) risk prediction utilizing the Cox proportional hazards model (Cox) and machine learning (ML). Design, setting, participants, and measurements: The Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE), a multicenter CKD cohort in China, was employed as the model’s training and testing datasets, with a split ratio of 7:3. A cohort from Peking University First Hospital (PKUFH cohort) served as the external validation dataset. The participants’ laboratory tests in those cohorts were conducted at PKUFH. We included individuals with CKD stages 1~4 at baseline. The incidence of kidney replacement therapy (KRT) was defined as the outcome. We constructed the Peking University-CKD (PKU-CKD) risk prediction model employing the Cox and ML methods, which include extreme gradient boosting (XGBoost) and survival support vector machine (SSVM). These models discriminate metrics by applying Harrell’s concordance index (Harrell’s C-index) and Uno’s concordance (Uno’s C). The calibration performance was measured by the Brier score and plots. Results: Of the 3216 C-STRIDE and 342 PKUFH participants, 411 (12.8%) and 25 (7.3%) experienced KRT with mean follow-up periods of 4.45 and 3.37 years, respectively. The features included in the PKU-CKD model were age, gender, estimated glomerular filtration rate (eGFR), urinary albumin–creatinine ratio (UACR), albumin, hemoglobin, medical history of type 2 diabetes mellitus (T2DM), and hypertension. In the test dataset, the values of the Cox model for Harrell’s C-index, Uno’s C-index, and Brier score were 0.834, 0.833, and 0.065, respectively. The XGBoost algorithm values for these metrics were 0.826, 0.825, and 0.066, respectively. The SSVM model yielded values of 0.748, 0.747, and 0.070, respectively, for the above parameters. The comparative analysis revealed no significant difference between XGBoost and Cox, in terms of Harrell’s C, Uno’s C, and the Brier score (p = 0.186, 0.213, and 0.41, respectively) in the test dataset. The SSVM model was significantly inferior to the previous two models (p < 0.001), in terms of discrimination and calibration. The validation dataset showed that XGBoost was superior to Cox, regarding Harrell’s C, Uno’s C, and the Brier score (p = 0.003, 0.027, and 0.032, respectively), while Cox and SSVM were almost identical concerning these three parameters (p = 0.102, 0.092, and 0.048, respectively). Conclusions: We developed and validated a new ESKD risk prediction model for patients with CKD, employing commonly measured indicators in clinical practice, and its overall performance was satisfactory. The conventional Cox regression and certain ML models exhibited equal accuracy in predicting the course of CKD. |
format | Online Article Text |
id | pubmed-9965616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99656162023-02-26 ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study Hui, Miao Ma, Jun Yang, Hongyu Gao, Bixia Wang, Fang Wang, Jinwei Lv, Jicheng Zhang, Luxia Yang, Li Zhao, Minghui J Clin Med Article Background and objectives: In light of the growing burden of chronic kidney disease (CKD), it is of particular importance to create disease prediction models that can assist healthcare providers in identifying cases of CKD individual risk and integrate risk-based care for disease progress management. The objective of this study was to develop and validate a new pragmatic end-stage kidney disease (ESKD) risk prediction utilizing the Cox proportional hazards model (Cox) and machine learning (ML). Design, setting, participants, and measurements: The Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE), a multicenter CKD cohort in China, was employed as the model’s training and testing datasets, with a split ratio of 7:3. A cohort from Peking University First Hospital (PKUFH cohort) served as the external validation dataset. The participants’ laboratory tests in those cohorts were conducted at PKUFH. We included individuals with CKD stages 1~4 at baseline. The incidence of kidney replacement therapy (KRT) was defined as the outcome. We constructed the Peking University-CKD (PKU-CKD) risk prediction model employing the Cox and ML methods, which include extreme gradient boosting (XGBoost) and survival support vector machine (SSVM). These models discriminate metrics by applying Harrell’s concordance index (Harrell’s C-index) and Uno’s concordance (Uno’s C). The calibration performance was measured by the Brier score and plots. Results: Of the 3216 C-STRIDE and 342 PKUFH participants, 411 (12.8%) and 25 (7.3%) experienced KRT with mean follow-up periods of 4.45 and 3.37 years, respectively. The features included in the PKU-CKD model were age, gender, estimated glomerular filtration rate (eGFR), urinary albumin–creatinine ratio (UACR), albumin, hemoglobin, medical history of type 2 diabetes mellitus (T2DM), and hypertension. In the test dataset, the values of the Cox model for Harrell’s C-index, Uno’s C-index, and Brier score were 0.834, 0.833, and 0.065, respectively. The XGBoost algorithm values for these metrics were 0.826, 0.825, and 0.066, respectively. The SSVM model yielded values of 0.748, 0.747, and 0.070, respectively, for the above parameters. The comparative analysis revealed no significant difference between XGBoost and Cox, in terms of Harrell’s C, Uno’s C, and the Brier score (p = 0.186, 0.213, and 0.41, respectively) in the test dataset. The SSVM model was significantly inferior to the previous two models (p < 0.001), in terms of discrimination and calibration. The validation dataset showed that XGBoost was superior to Cox, regarding Harrell’s C, Uno’s C, and the Brier score (p = 0.003, 0.027, and 0.032, respectively), while Cox and SSVM were almost identical concerning these three parameters (p = 0.102, 0.092, and 0.048, respectively). Conclusions: We developed and validated a new ESKD risk prediction model for patients with CKD, employing commonly measured indicators in clinical practice, and its overall performance was satisfactory. The conventional Cox regression and certain ML models exhibited equal accuracy in predicting the course of CKD. MDPI 2023-02-14 /pmc/articles/PMC9965616/ /pubmed/36836039 http://dx.doi.org/10.3390/jcm12041504 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hui, Miao Ma, Jun Yang, Hongyu Gao, Bixia Wang, Fang Wang, Jinwei Lv, Jicheng Zhang, Luxia Yang, Li Zhao, Minghui ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title | ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title_full | ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title_fullStr | ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title_full_unstemmed | ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title_short | ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study |
title_sort | eskd risk prediction model in a multicenter chronic kidney disease cohort in china: a derivation, validation, and comparison study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965616/ https://www.ncbi.nlm.nih.gov/pubmed/36836039 http://dx.doi.org/10.3390/jcm12041504 |
work_keys_str_mv | AT huimiao eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT majun eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT yanghongyu eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT gaobixia eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT wangfang eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT wangjinwei eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT lvjicheng eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT zhangluxia eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT yangli eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy AT zhaominghui eskdriskpredictionmodelinamulticenterchronickidneydiseasecohortinchinaaderivationvalidationandcomparisonstudy |